NEWS
Oncode Investigator Miao-Ping Chien (Erasmus MC) in collaboration with SkylineDx received a TKI-LSH PPP Allowance to kickstart a project aimed at investigating the underlying mechanisms that drive metastasis in head and neck squamous cell carcinoma (HNSCC). Their approach is to leverage FUNseq, a cutting-edge technology developed and validated in Chien’s lab, to functionally profile the aggressive subpopulations of cancer cells and characterize them by single-cell sequencing.
For this, they will collaborate with head and neck surgeons from Erasmus MC. The discovered mechanisms can yield new knowledge and insight into the process of metastasis in HNSCC and inform the design of new diagnostic and treatment strategies.
HNSCC remains one of the most common cancers worldwide. Despite the development of innovative therapies over the last years, the mortality rate is still 50%. Such low survival rates are attributed to tumor recurrence and (distant) metastasis and are partly also caused by a lack of robust biomarkers to predict treatment response.
Currently, the prognosis and the risk stratification of HNSCC patients are based exclusively on clinico-pathological features including age, tumor size, morphology, and tumor grade. However, these conventional characteristics have proven to be insufficient to accurately predict treatment outcomes and survival. The lack of efficient (predictive) biomarkers contributes to the dismally low median overall survival of only 6-15 months for patients with inoperable recurrent or distant metastatic HNSCC. There is, therefore, a high unmet need for improved biomarkers that can help predict metastasis, and risk-stratify the patients, thus enabling more risk-based design of intervention strategies (e.g., surveillance intensity and immunotherapy eligibility), and improving survival for patients with HNSCC.
This newly funded collaboration between Oncode Investigator Miao-Ping Chien, molecular diagnostics company SkylineDx, and surgeons at Erasmus MC - aims to tackle this unmet need and bring significant changes for HNSCC patients. “Together with SkylineDx, and in collaboration with Jose Hardillo, a head and neck surgeon at Erasmus MC, we aim to identify predictive signatures of tumor metastasis and therapeutic targets for HNSCC, and to tackle the poor prognosis of the disease, caused by metastases” says Chien. “The funding allows all involved parties to kickstart the collaboration. We can now collect single-cell profile HNSCC tumor samples and identify and validate target genes. And with the help of SkylineDx and Oncode we hope to bring this knowledge to the clinic" adds Chien.
“We are honored to be at the forefront of discovery in HNSCC in collaboration with some of the smartest minds in this field,” says Jvalini Dwarkasing, Chief Scientific Officer of SkylineDx. “We look forward to applying our prognostic risk stratification tools with the technology developed by Miao-Ping Chien team to discover new biomarkers for clinical use with the aim of improving the treatment and outcomes for these patients.”
ROTTERDAM, Netherlands and SAN DIEGO, U.S. April 20, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first
read moreROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 17, 2023: SkylineDx, an innovative diagnostics company, focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced the
read moreROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 1, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces the commercial launch of Merlin Assay as CE-IVD distributable test kit in Europe. Merlin Assay
read moreROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), May 25, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces Medicare coverage for Merlin Test. The local coverage determination was issued under the foundational policy
read moreROTTERDAM (the Netherlands), SAN DIEGO (USA), April 26, 2022: Today, SkylineDx, a leading molecular diagnostics company, announced the addition of new leadership to reinforce their commitment to bringing personalized diagnostics to the US
read moreROTTERDAM (the Netherlands), SAN DIEGO (USA), April 21, 2022: Today, SkylineDx presents new data showing that their Merlin Test was able to prospectively reduce >37% of surgeries in a non-interventional study for newly diagnosed melanoma
read moreROTTERDAM (the Netherlands), SAN DIEGO (USA), March 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients was independently validated in a Swedish (European) cohort, where it could reduce approximately a third of
read moreROTTERDAM (the Netherlands), SAN DIEGO (USA), February 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients would have been able to reduce over 59% of surgery-related complications by means of deselecting
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), GHENT (Belgium), December 22, 2021: Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused
read moreROTTERDAM (the Netherlands), SAN DIEGO (USA), December 21, 2021: today, SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux’ largest biotech
read moreROTTERDAM (the Netherlands), SAN DIEGO (California, US), November 9, 2021: today, SkylineDx announced that the Accreditation Committee of the College of American Pathologists (CAP) has renewed accreditation to
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), October 12, 2021: today, SkylineDx announced it has entered into an exclusive patent license agreement with Imperial College London for the worldwide development and commercialization of a
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), June 24, 2021: Today, SkylineDx announced to invest in research and development in the field of Squamous Cell Carcinoma (SCC), as part of a Dutch consortium including the Erasmus MC Cancer
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), June 10, 2021: Today, SkylineDx announced that the first hospitals will start including melanoma patients in a large prospective clinical study in the United States, to validate the Merlin Assay.
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), April 30, 2021: SkylineDx announced that the performance of their melanoma diagnostic test (Merlin Assay) is confirmed in an independent group of U.S. patients from the Mayo Clinic and West
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), April 22, 2021: SkylineDx and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announce the signing of a new partnership agreement which targets
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), March 23, 2021: SkylineDx received the first Merlin Assay clinical test requests and therefore reported initial gross sales ahead of the commercial launch at the World Congress of Melanoma (WCM)
read moreROTTERDAM (The Netherlands) and SAN DIEGO (US), February 23, 2021: today, SkylineDx announces to have signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm RAINFOREST. This
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), February 18, 2021: today, SkylineDx announced that it received the esteemed ISO 13485:2016 Quality Management System certificate from notified body BSI Netherlands, after their successful audit
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), February 15, 2021: today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer) at
read moreROTTERDAM (the Netherlands), SAN DIEGO (US), LONDON (UK), September 10, 2020: SkylineDx, announces a collaboration agreement with Professor Michael Levin’s group at Imperial College London and Professor Jane Burns’ group at
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), August 26, 2020: SkylineDx signed a collaboration agreement with a multi-disciplinary clinical consortium in the Netherlands that designed a trial to implement a diagnostic innovation to manage
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), June 23, 2020: last week, SkylineDx signed the 10th collaboration agreement with an academic partner for research under the extensive Falcon R&D Program to further validate both melanoma
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), May 14, 2020: SkylineDx announces the publication of two ASCO abstracts describing a biomarker that identifies a subgroup of skin cancer (cutaneous melanoma) patients that could benefit from
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), May 12, 2020: Everything Genetic Ltd has partnered with a leading private health insurance company in the UK to design an access strategy for patients with multiple myeloma (blood cancer) to
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), April 22, 2020: SkylineDx announced today that the Merlin Assay for melanoma is officially added to their test menu and available as Laboratory Developed Test from their CAP/CLIA lab in San
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), April 15, 2020: SkylineDx in collaboration with the Mayo Clinic published yesterday its first study describing a diagnostic test that could reduce up to 42% of surgical interventions used to
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), March 24, 2020: SkylineDx today announces an agreement with BioInvent International AB (OMXS: BINV) to characterize the gene expression and immunological signatures in tumors of patients pre-
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), March 17, 2020: multiple myeloma (blood cancer) patients with a high risk or aggressive course of the disease are unlikely to benefit from current treatment approaches, including lenalidomide
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), February 4, 2020: SkylineDx is excited to announce the scientific collaboration with the Multiple Myeloma (blood cancer) specialized department of the Wuerzburg University Medical Center II
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), September 30, 2019: SkylineDx announced, during the European Society for Medical Oncology congress (Barcelona, EU), that it successfully validated the performance of their skin cancer
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), September 24, 2019: SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester (MN, US) the launch of a pilot study it will conduct with the
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), September 12, 2019: fast-progressing multiple myeloma (blood cancer) patients of 65 years and older that won’t undergo a stem cell transplantation live 42 months longer when treated with
read moreTranslation of Dutch newspaper (Het Financieele Dagblad) article written by Thieu Vaessen. Source can be found via this link. *** Van Herk puts € 20 million into diagnostics company for skin cancer The
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), September 2, 2019: Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), July 25th, 2019: hematologists and multiple myeloma (blood cancer) patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), July 23rd, 2019: the academic hematology department of Erasmus Medical Center (EMC) is globally the first hospital to offer every multiple myeloma (blood cancer) patient an innovative
read moreROTTERDAM en SAN DIEGO (Verenigde Staten), 23 juli 2019: de hematologie afdeling van het Erasmus Medisch Centrum (EMC) is wereldwijd het eerste ziekenhuis dat elke multipel myeloom (bloedkanker) patiënt een innovatieve diagnostische
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), June 26th, 2019: the Rotterdam headquartered diagnostics company has been granted CAP (College of American Pathologists) accreditation, following its CLIA (Clinical Laboratory Improvement
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), June 13th, 2019: a substantial number of blood cancer (multiple myeloma) patients could make more informed decisions on their treatment if more information becomes available for them and their
read moreROTTERDAM en SAN DIEGO (Verenigde Staten), 13 juni 2019: een aanzienlijk aantal bloedkanker (multipel myeloom) patiënten kunnen beter beslissen over een behandeling als er meer informatie over hun diagnose beschikbaar komt voor hen en
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), November 28, 2018: an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk
read moreROTTERDAM (the Netherlands) and SAN DIEGO (US), September 27, 2018: Netherlands Enterprise Agency (“Rijksdienst voor Ondernemend Nederland”), a part of the Ministry of Economic Affairs and Climate Policy, grants through a
read moreROTTERDAM en SAN DIEGO (USA), 27 september, 2018: Rijksdienst voor Ondernemend Nederland (RVO), een onderdeel van het ministerie van Economische Zaken en Klimaat, kent, middels Innovatiekrediet, € 2,7 miljoen toe aan de ontwikkeling van
read moreROTTERDAM, the Netherlands and SAN DIEGO USA, July 30th, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels on the algorithm GESTURE [1] that links individual cancer patients to
read moreROTTERDAM en SAN DIEGO (USA), 30 juli, 2018: Wetenschappelijk tijdschrift Nature Communications publiceerde 27 juli 2018 het onderzoekspaper van Joske Ubels over het GESTURE [1] algoritme dat individuele kankerpatiënten koppelt aan een
read moreROTTERDAM, the Netherlands and SAN DIEGO, USA, August 1, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels about a novel machine learning concept that derives predictive
read moreSKY92 risk stratification at relapse provides additional prognostic information for standardrisk Multiple Myeloma patients RNA-Seq based risk stratification in Multiple Myeloma patients validates SKY92 as a high-risk marker in the
read moreRotterdam, the Netherlands, January 31, 2018 – SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the
read moreFirst Validation of SKY92 Prognostic Signature in Bortezomib-Thalidomide-Dexamethasone (VTD) Setting Additional Data Yield Key Insights into Biology of Multiple Myeloma and Inform Design of Myeloma UK (MUK) Nine OPTIMUM Trial
read morePoster Presentation at ISPOR European Congress Demonstrates Cost-savings and HealthGenerating Benefits of SKY92 Rotterdam, the Netherlands and Laguna Hills, CA, November 13, 2017 – SkylineDx announced new data from the 20th
read moreICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 12, 2017 – SkylineDx today
read moreClinical Lymphoma, Myeloma and Leukemia Paper Validates Use of SKY92 and its Combination with International Staging System (ISS) Rotterdam, the Netherlands and Laguna Hills, CA, July 25, 2017 – SkylineDx today announced the
read morePresentation at BioSB 2017 Demonstrated Value of GESTURE™ for Identifying Patient Subgroups Likely to Benefit from Anti-Cancer Treatment Rotterdam, the Netherlands and Laguna Hills, CA, April 10, 2017 – SkylineDx
read moreNew Studies Demonstrate Value of Gene Expression Risk Profiling to Identify Ultra-High-Risk Multiple Myeloma Patients Rotterdam, the Netherlands and Laguna Hills, CA, November 29, 2016 – SkylineDx today announced the
read moreThe Japanese Patent Office Has Notified SkylineDx of the Decision to Grant a Patent for the SKY92 Gene Signature Rotterdam, the Netherlands, Laguna Hills, CA, Tokyo, Japan, October 11, 2016 - SkylineDx is pleased to announce
read moreProject Focuses on Development of Gene Expression Profiling Tool to Predict Treatment Outcomes for Patients with Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 4, 2016 - SkylineDx today announced
read moreStudies Support Validity of SKY92 as a Superior Predictor of Risk Stratification in Newly Diagnosed and Relapsed Patients Rotterdam, the Netherlands and Laguna Hills, CA, May 31, 2016 - SkylineDx today announced the
read moreROTTERDAM, Netherlands and LAGUNA HILLS, Calif., March 8, 2016 -- SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma Foundation (IMF) to
read moreStudies Support Use of MMprofiler™ for Stratifying High and Low-Risk in Newly Diagnosed Elderly and Relapsed Patients MassGen Poster Highlights Use of MMprofiler™ in Phase II Modified RVD
read moreCE-IVD Approval Marks SkylineDx’s European Commercialization of its MMprofiler technology Rotterdam, the Netherlands and Laguna Hills, CA, November 25, 2015 – SkylineDx, today announced they have received CE-IVD
read moreArticle in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients Rotterdam, the Netherlands, 8 September 2015 – Researchers at
read moreKey additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product Rotterdam, The Netherlands, 19 August 2015 - SkylineDx, a
read moreTest of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the
read moreBoston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple Myeloma (MM) patients and the clinical
read more